Anal submucosal injection: a new route for drug administration in pelvic @entity5 . II. XXXX anal injection in the treatment of advanced @entity150 . Preliminary study.

@entity1 @entity137 @entity19 @entity5 @entity150 @entity1499
The clinical efficacy of submucosal anal injections of @entity1499 in advanced @entity150 is investigated. An experimental study on 20 @entity19 has shown that @entity1499 injected into the anal submucosa has no clinicopathological effect on the anorectum. The clinical study comprised 18 @entity1 with advanced @entity150 (13 with stage T3 and 5 with stage T4 disease) as a test group in whom @entity1499 was injected into the anal submucosa and 8 (6 with stage T3 and 2 with stage T4 @entity5 ) treated concurrently with intravenous @entity1499 . The dose in both groups was 50 mg. every 5 days for 5 consecutive doses. The course was repeated at 3-week intervals. Most @entity1 received @entity1499 as outpatients. @entity1499 blood levels were measured 4 and 24 hours after administration in both groups. In the test group 10 of the 18 @entity1 showed complete @entity5 regression and were alive 21 to 50 months after the start of treatment. Partial regression was observed in 8 @entity1 . Hematological reserve remained unchanged. Mild @entity137 occurred in 3 @entity1 . Of the 8 @entity1 treated intravenously the @entity5 showed partial regression in 1, was stable in 3 and progressed in 4. Side effects were severe in 5 @entity1 . Our results show that @entity1499 injection is highly effective in the treatment of advanced @entity150 . It is safe, well tolerated and can be used on an outpatient basis.
